Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: Implications to autoimmune disorders and organ transplantation

Wen Shin Lee, Katalin Erdelyi, Csaba Matyas, Partha Mukhopadhyay, Zoltan V. Varga, Lucas Liaudet, G. Haskó, Daniela Čiháková, Raphael Mechoulam, Pal Pacher

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a nonpsychoactive constituent of marijuana that exerts antiinflammatory effects independent of classical cannabinoid receptors. Recently, 80 clinical trials have investigated the effects of CBD in various diseases from inflammatory bowel disease to graft versus host disease. CBD-based formulations are used for the management of multiple sclerosis in numerous countries, and CBD also received U.S. Food and Drug Administration approval for the treatment of refractory childhood epilepsy and glioblastoma multiforme. Herein, using a well-established mouse model of experimental autoimmune myocarditis (EAM) induced by immunization with cardiac myosin emmulsified in adjuvant resulting in T cell–mediated inflammation, cardiomyocyte cell death, fibrosis and myocardial dysfunction, we studied the potential beneficial effects of CBD. EAM was characterized by marked myocardial T-cell infiltration, profound inflammatory response and fibrosis (measured by quantitative real-time polymerase chain reaction, histology and immunohistochemistry analyses) accompanied by marked attenuation of both systolic and diastolic cardiac functions measured with a pressure-volume conductance catheter technique. Chronic treatment with CBD largely attenuated the CD3+ and CD4+ T cell–mediated inflammatory response and injury, myocardial fibrosis and cardiac dysfunction in mice. In conclusion, CBD may represent a promising novel treatment for managing autoimmune myocarditis and possibly other autoimmune disorders and organ transplantation.

Original languageEnglish
Pages (from-to)136-146
Number of pages11
JournalMolecular Medicine
Volume22
DOIs
Publication statusPublished - 2016

Fingerprint

Cannabidiol
Myocarditis
Organ Transplantation
Cardiac Myosins
Fibrosis
Therapeutics
Drug Approval
Cannabinoid Receptors
Sudden Cardiac Death
Autoantigens
Graft vs Host Disease
Cannabis
Glioblastoma
Immunosuppressive Agents
Inflammatory Bowel Diseases
Cardiac Myocytes
Multiple Sclerosis
Real-Time Polymerase Chain Reaction
Young Adult
Immunization

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Cannabidiol limits T cell–mediated chronic autoimmune myocarditis : Implications to autoimmune disorders and organ transplantation. / Lee, Wen Shin; Erdelyi, Katalin; Matyas, Csaba; Mukhopadhyay, Partha; Varga, Zoltan V.; Liaudet, Lucas; Haskó, G.; Čiháková, Daniela; Mechoulam, Raphael; Pacher, Pal.

In: Molecular Medicine, Vol. 22, 2016, p. 136-146.

Research output: Contribution to journalArticle

Lee, WS, Erdelyi, K, Matyas, C, Mukhopadhyay, P, Varga, ZV, Liaudet, L, Haskó, G, Čiháková, D, Mechoulam, R & Pacher, P 2016, 'Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: Implications to autoimmune disorders and organ transplantation', Molecular Medicine, vol. 22, pp. 136-146. https://doi.org/10.2119/molmed.2016.00007
Lee, Wen Shin ; Erdelyi, Katalin ; Matyas, Csaba ; Mukhopadhyay, Partha ; Varga, Zoltan V. ; Liaudet, Lucas ; Haskó, G. ; Čiháková, Daniela ; Mechoulam, Raphael ; Pacher, Pal. / Cannabidiol limits T cell–mediated chronic autoimmune myocarditis : Implications to autoimmune disorders and organ transplantation. In: Molecular Medicine. 2016 ; Vol. 22. pp. 136-146.
@article{19cdfaa2f035470ea3b0d2cecb258ef9,
title = "Cannabidiol limits T cell–mediated chronic autoimmune myocarditis: Implications to autoimmune disorders and organ transplantation",
abstract = "Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a nonpsychoactive constituent of marijuana that exerts antiinflammatory effects independent of classical cannabinoid receptors. Recently, 80 clinical trials have investigated the effects of CBD in various diseases from inflammatory bowel disease to graft versus host disease. CBD-based formulations are used for the management of multiple sclerosis in numerous countries, and CBD also received U.S. Food and Drug Administration approval for the treatment of refractory childhood epilepsy and glioblastoma multiforme. Herein, using a well-established mouse model of experimental autoimmune myocarditis (EAM) induced by immunization with cardiac myosin emmulsified in adjuvant resulting in T cell–mediated inflammation, cardiomyocyte cell death, fibrosis and myocardial dysfunction, we studied the potential beneficial effects of CBD. EAM was characterized by marked myocardial T-cell infiltration, profound inflammatory response and fibrosis (measured by quantitative real-time polymerase chain reaction, histology and immunohistochemistry analyses) accompanied by marked attenuation of both systolic and diastolic cardiac functions measured with a pressure-volume conductance catheter technique. Chronic treatment with CBD largely attenuated the CD3+ and CD4+ T cell–mediated inflammatory response and injury, myocardial fibrosis and cardiac dysfunction in mice. In conclusion, CBD may represent a promising novel treatment for managing autoimmune myocarditis and possibly other autoimmune disorders and organ transplantation.",
author = "Lee, {Wen Shin} and Katalin Erdelyi and Csaba Matyas and Partha Mukhopadhyay and Varga, {Zoltan V.} and Lucas Liaudet and G. Hask{\'o} and Daniela Čih{\'a}kov{\'a} and Raphael Mechoulam and Pal Pacher",
year = "2016",
doi = "10.2119/molmed.2016.00007",
language = "English",
volume = "22",
pages = "136--146",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",

}

TY - JOUR

T1 - Cannabidiol limits T cell–mediated chronic autoimmune myocarditis

T2 - Implications to autoimmune disorders and organ transplantation

AU - Lee, Wen Shin

AU - Erdelyi, Katalin

AU - Matyas, Csaba

AU - Mukhopadhyay, Partha

AU - Varga, Zoltan V.

AU - Liaudet, Lucas

AU - Haskó, G.

AU - Čiháková, Daniela

AU - Mechoulam, Raphael

AU - Pacher, Pal

PY - 2016

Y1 - 2016

N2 - Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a nonpsychoactive constituent of marijuana that exerts antiinflammatory effects independent of classical cannabinoid receptors. Recently, 80 clinical trials have investigated the effects of CBD in various diseases from inflammatory bowel disease to graft versus host disease. CBD-based formulations are used for the management of multiple sclerosis in numerous countries, and CBD also received U.S. Food and Drug Administration approval for the treatment of refractory childhood epilepsy and glioblastoma multiforme. Herein, using a well-established mouse model of experimental autoimmune myocarditis (EAM) induced by immunization with cardiac myosin emmulsified in adjuvant resulting in T cell–mediated inflammation, cardiomyocyte cell death, fibrosis and myocardial dysfunction, we studied the potential beneficial effects of CBD. EAM was characterized by marked myocardial T-cell infiltration, profound inflammatory response and fibrosis (measured by quantitative real-time polymerase chain reaction, histology and immunohistochemistry analyses) accompanied by marked attenuation of both systolic and diastolic cardiac functions measured with a pressure-volume conductance catheter technique. Chronic treatment with CBD largely attenuated the CD3+ and CD4+ T cell–mediated inflammatory response and injury, myocardial fibrosis and cardiac dysfunction in mice. In conclusion, CBD may represent a promising novel treatment for managing autoimmune myocarditis and possibly other autoimmune disorders and organ transplantation.

AB - Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with autoimmune processes in which cardiac myosin is a major autoantigen. Conventional immunosuppressive therapies often provide unsatisfactory results and are associated with adverse toxicities during the treatment of autoimmune myocarditis. Cannabidiol (CBD) is a nonpsychoactive constituent of marijuana that exerts antiinflammatory effects independent of classical cannabinoid receptors. Recently, 80 clinical trials have investigated the effects of CBD in various diseases from inflammatory bowel disease to graft versus host disease. CBD-based formulations are used for the management of multiple sclerosis in numerous countries, and CBD also received U.S. Food and Drug Administration approval for the treatment of refractory childhood epilepsy and glioblastoma multiforme. Herein, using a well-established mouse model of experimental autoimmune myocarditis (EAM) induced by immunization with cardiac myosin emmulsified in adjuvant resulting in T cell–mediated inflammation, cardiomyocyte cell death, fibrosis and myocardial dysfunction, we studied the potential beneficial effects of CBD. EAM was characterized by marked myocardial T-cell infiltration, profound inflammatory response and fibrosis (measured by quantitative real-time polymerase chain reaction, histology and immunohistochemistry analyses) accompanied by marked attenuation of both systolic and diastolic cardiac functions measured with a pressure-volume conductance catheter technique. Chronic treatment with CBD largely attenuated the CD3+ and CD4+ T cell–mediated inflammatory response and injury, myocardial fibrosis and cardiac dysfunction in mice. In conclusion, CBD may represent a promising novel treatment for managing autoimmune myocarditis and possibly other autoimmune disorders and organ transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84987630537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987630537&partnerID=8YFLogxK

U2 - 10.2119/molmed.2016.00007

DO - 10.2119/molmed.2016.00007

M3 - Article

AN - SCOPUS:84987630537

VL - 22

SP - 136

EP - 146

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

ER -